CYP1B1 and malignant colon neoplasm: These in silico findings, together with great effects on SW-480 and HT-29 colon cancer cells, provide a foundation for further experimental validation and characterization of isorhamnetin’s interactions with target proteins, including CYP1A1, CYP1B1, P-gp, MRP1, and MRP5.